Jason Cole, Chief Strategy and Financial Officer, to Depart bluebird bio This Fall
September 12 2022 - 7:30AM
Business Wire
Company has initiated an external search for
its next CFO
bluebird bio, Inc. (NASDAQ: BLUE) today announced that Jason
Cole, Chief Strategy and Financial Officer, plans to leave bluebird
bio to pursue new career opportunities.
Throughout his 8.5 years at bluebird, Mr. Cole has held multiple
roles including General Counsel/Chief Legal Officer (2014-2019),
Chief Operating & Legal Officer (2019-2021) and Chief Business
Officer (2021-2022). Throughout his tenure, Mr. Cole helped guide
bluebird’s evolution from a small clinical stage biotech to a
commercial company and has helped bluebird navigate periods of
tremendous change.
In March 2022, Mr. Cole was appointed Chief Strategy and
Financial Officer at a critical juncture for the company. He led
changes to stabilize the Company’s financial position and
strengthen its balance sheet. Since that time, he has also served
as Principal Financial Officer and Principal Accounting
Officer.
“Jason is the quintessential bluebird – with a deep commitment
to the patients and families we aspire to treat, to our business,
and to the culture that makes bluebird so unique,” said Andrew
Obenshain, CEO, bluebird bio. “We are extremely grateful to Jason
for stepping in as CFO during a difficult time for the company. His
experience and thoughtful approach have been a stabilizing force
through a period of significant change. Under Jason’s leadership,
we have solidified our financial position and financing plans and
have laid the foundation to operate as a commercial company.”
Over the coming weeks, Mr. Cole intends to transition finance
responsibilities to Katherine Breedis, an experienced business and
financial executive from Danforth Advisors, who is expected to
serve as interim CFO. bluebird has initiated an external search for
its next CFO, with a focus on experience with commercial stage
companies. Mr. Cole’s management responsibilities for strategy,
external affairs and operations will be transitioned to Andrew
Obenshain.
Mr. Cole’s last day will be October 14, 2022; he expects to
continue to consult with bluebird on corporate strategy through
April 2023.
About bluebird bio, Inc.
bluebird bio is pursuing curative gene therapies to give
patients and their families more bluebird days. With a dedicated
focus on severe genetic diseases, bluebird has industry-leading
clinical and research programs for sickle cell disease,
beta-thalassemia and cerebral adrenoleukodystrophy and is advancing
research to apply new technologies to these and other diseases. We
custom design each of our therapies to address the underlying cause
of disease and have developed in-depth and effective analytical
methods to understand the safety of our lentiviral vector
technologies and drive the field of gene therapy forward.
Founded in 2010, bluebird has the largest and deepest ex-vivo
gene therapy data set in the world—setting the standard for
industry. Today, bluebird continues to forge new paths, combining
our real-world experience with a deep commitment to patient
communities and a people-centric culture that attracts and grows a
diverse flock of dedicated birds.
For more information, visit bluebirdbio.com or follow us
on social media at @bluebirdbio, LinkedIn,
Instagram and YouTube.
bluebird bio Cautionary Statement Regarding Forward-Looking
Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements that are not statements of historical facts
are, or may be deemed to be, forward-looking statements, including
but not limited to our statements regarding the timing for
recruiting and integrating a permanent CFO, the intention to engage
Katherine Breedis as an interim CFO, and the expectation that Jason
Cole will continue to consult for the Company. Such forward-looking
statements are based on current expectations about our future
goals, plans and objectives and involve inherent risks, assumptions
and uncertainties, including internal or external factors that
could delay, divert or change any of them in the next several
years, that are difficult to predict, may be beyond our control and
could cause our future financial results, goals, plans and
objectives to differ materially from those expressed in, or implied
by, the statements. No forward-looking statement can be guaranteed.
Forward-looking statements in this press release should be
evaluated together with the many risks and uncertainties that
affect bluebird bio’s business, particularly those identified in
the risk factors discussion in bluebird bio’s Annual Report on Form
10-K, as updated by our subsequent Quarterly Reports on Form 10-Q,
Current Reports on Form 8-K and other filings with the Securities
and Exchange Commission. The forward-looking statements included in
this document are made only as of the date of this document and
except as otherwise required by applicable law, bluebird bio
undertakes no obligation to publicly update or revise any
forward-looking statement, whether as a result of new information,
future events, changed circumstances or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220912005463/en/
Investors: Courtney O’Leary, 978-621-7347
coleary@bluebirdbio.com
or
Media: Sarah Alspach, 215-287-6354
sarah.alspach@bluebirdbio.com
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Mar 2024 to Apr 2024
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Apr 2023 to Apr 2024